Comparing the current results to its competitors, Precision Optics Inc reported Revenue increase in the 3 quarter 2026 by 108.04 % year on year, while most of its competitors have experienced contraction in revenues by -2.15 %, achieved in the same quarter.
Precision Optics Corporation Inc , slower than the average decrease reported by the company's competitors of -52.77 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -52.77 %
Precision Optics Inc 's Comment on Competition and Industry Peers
The company operates in highly competitive markets alongside both domestic and foreign manufacturers, many of which are larger and possess greater resources. There is a risk that other companies with more experience in the optics industry and greater financial resources may enter the market and compete directly. The company's success depends on maintaining a technological advantage and integrating technology into custom designs, supported by internal engineering, research and development, and patent protection. Its technical capabilities in Microprecision™ optics, micro medical cameras, digital imaging, and illumination serve as competitive factors in the minimally invasive surgical device market.
Due to outstanding performance in Overall company, revenue grew by 108.04 % Precision Optics Corporation Inc improved its market share, to approximately 0.06 %.
June 5, 2025
Precision Optics Corporation, a notable player in the optical and imaging systems industry, has announced a significant expansion of its facilities to accommodate its growing backlog of orders. In a strategic decision, the company has signed a lease to relocate its corporate offices and engineering development operations to new premises in Littleton, Massachusetts.This move comes amid a surge in demand for Precision Optics’ innovative products, which are used in a wide range of applications, including medical devices, aerospace, and consumer electronics. The new facility is expected to provide the company with enhanced capabilities to support its engineering teams and streamline operations, ultimately lead...
April 18, 2024
Precision Optics Corporation, Inc. (NASDAQ: POCI) announced recently that it has secured a significant order of $720,000. This comes from a top-tier defense and aerospace customer who tapped the company for a commercial application involving its proprietary manufacturing technology. This technology is particularly formulated for high precision micro-optics systems. This new announcement reinforces Precision Optics commitment to developing and manufacturing superior advanced optical instruments for its influential and diverse clientele.Founded in Massachusetts, Precision Optics Corporation Inc. has remained an industry leader in optical instruments for two prominent sectors: medical and defense. The company ...
Publicly Traded Peers of Precision Optics Corporation Inc
Baxter International Inc Share Performance
-1.15%
Over The Past 5 Days
Baxter International Inc
Profile
Baxter International Inc is a global healthcare company that specializes in providing a wide range of medical products and services. They operate through various business segments including Pharmaceuticals, Medical Products, and Renal Care, offering solutions for hospitals, clinics, and home-based healthcare settings.
Lantheus Holdings Inc operates as a medical imaging company that develops and commercializes diagnostic imaging agents. The company focuses on providing innovative imaging agents to enhance medical diagnostics processes and improve patient outcomes. Lantheus mainly generates revenue from the sales of its products and imaging agents to healthcare providers and institutions globally.
Inmode Ltd is a medical technology company that specializes in developing and commercializing minimally invasive aesthetic and medical solutions. They primarily operate on a direct-to-consumer model, selling their devices to physicians, medical spas, and clinics. In addition to device sales, they generate recurring revenue through consumable product sales and service contracts for their devices.
Haemonetics Corporation's business model revolves around providing innovative solutions and technologies for the collection, processing, and management of blood and its components.
Cytosorbents Corporation operates on a business model that focuses on the development and commercialization of novel products for blood purification. The company manufactures and sells its flagship product, CytoSorb, which is a blood purification technology designed to reduce cytokine storm in critically ill patients. Cytosorbents generates revenue by selling CytoSorb to hospitals, clinics, and healthcare providers globally.
Sources:
Precision Optics Corporation Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Precision Optics Corporation Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
